Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RaQualia Pharma's Enterprise Value is 円10,809 Mil.
RaQualia Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円-448 Mil. Therefore, RaQualia Pharma's EV-to-EBIT ratio for today is -24.10.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, RaQualia Pharma's Enterprise Value is 円10,809 Mil.
RaQualia Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円-218 Mil. Therefore, RaQualia Pharma's EV-to-EBITDA ratio for today is -49.65.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, RaQualia Pharma's Enterprise Value is 円10,809 Mil.
RaQualia Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,373 Mil. Therefore, RaQualia Pharma's EV-to-Revenue ratio for today is 7.88.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, RaQualia Pharma's Enterprise Value is 円10,809 Mil.
RaQualia Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円264 Mil. Therefore, RaQualia Pharma's EV-to-FCF ratio for today is 40.95.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
RaQualia Pharma (TSE:4579) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
RaQualia Pharma's current Enterprise Value is 円10,809 Mil.
RaQualia Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-448 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
RaQualia Pharma's current Enterprise Value is 円10,809 Mil.
RaQualia Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-218 Mil.
RaQualia Pharma's current Enterprise Value is 円10,809 Mil.
RaQualia Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,373 Mil.
RaQualia Pharma's current Enterprise Value is 円10,809 Mil.
RaQualia Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円315 Mil.
RaQualia Pharma's current Enterprise Value is 円10,809 Mil.
RaQualia Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円264 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma Enterprise Value Related Terms
RaQualia Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, RaQualia Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
RaQualia Pharma's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Enterprise Value of 円10,809 Mil as of Jul. 08, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Enterprise Value too high?
RaQualia Pharma's current Enterprise Value is 円10,809 Mil. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Enterprise Value compare to VRTX and REGN?
RaQualia Pharma's Enterprise Value of 円10,809 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Enterprise Value is 円10,809 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Enterprise Value is 円10,809 Mil. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Enterprise Value is 円10,809 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Enterprise Value: 円10,809 Mil
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
